All Insights

LLY and AZN delivered 25-40% annualized returns over a decade while PFE and NVO badly trailed the S&P 500 — proof that pharma sector exposure matters far less than stock selection. A complete framework covering mega-cap divergence, the structural $300B M&A tailwind facing small/mid-cap biotechs, and five distinct exit pathways beyond acquisition.

LLY, AZN, and ABBV significantly outperformed the S&P 500 over 5-10 years; JNJ, NVO, and PFE meaningfully lagged — with LLY's two GLP-1 drugs alone now over 60% of revenue. A full benchmark of all eight mega-cap pharma names, and why passive sector exposure has badly underperformed disciplined stock selection.

Investing in Roche, AstraZeneca, and Eli Lilly captures both the biology wave and the AI productivity wave — without paying the 35x P/E premium of pure-play AI stocks. A dimension-by-dimension comparison of AI/tech vs. pharma, ending in a specific 40-60% allocation recommendation.

All three portfolios — Income & Stability, Balanced Growth, High Conviction — target positive long-term returns; the only real difference is how those returns arrive: dividend income or capital appreciation. Specific allocations, projected returns, and rebalancing triggers for each risk profile.

Four BUYs (AstraZeneca, Merck, Roche, Eli Lilly), four HOLDs, zero SELLs — a full verdict on eight leading pharma companies, scored across pipeline strength, financial health, valuation, and patent cliff exposure as of April 2026.

A $500M fund returning $2B in profits generates $300M in carry — but GPs only get paid after LPs recover their full capital first. Why the "VCs invest their own money" assumption is wrong, and what that fiduciary structure actually means for founders, LPs, and anyone trying to break into venture.

The highest-value health care opportunities sit at the intersection of technology, care coordination, and underserved populations — home-based care, mental health platforms, and AI-diagnostics carry the most durable structural tailwinds. A strategic map of the sector's core tensions and where each stakeholder group should focus.